Philips showcases its latest portfolio of cardiology innovations that deliver clinical confidence and efficiency in treating cardiac disease at EuroPCR 2023

Amsterdam, the Netherlands – Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, is showcasing end-to-end cardiology solutions through the care pathway at the annual meeting for the European Association of Percutaneous Cardiovascular Interventions(EuroPCR, May 16-19, Paris, France) to deliver better heart care for patients with greater efficiency. The Philips cardiology portfolio addresses the need for integrating imaging, devices, software, informatics, and services at each point in the cardiac patient journey. Philips’ proven physiology technologies can enable interventionalists to perform ultra-low contrast percutaneous coronary intervention (ULC-PCI) procedures with greater confidence.

In line with the company’s commitment to supporting its innovations with clinical evidence, Philips’ clinical partners will present new data during late-breaking sessions at EuroPCR that could help inform treatment for PCI patients.

Philips Dynamic Coronary Roadmap (DCR) to reduce the total iodinated contrast media volumes administered during percutaneous coronary intervention (PCI) procedures, compared to PCI performed without DCR guidance. The late-breaker presentation will take place on Tuesday, May 16 at 12:00 to 13:30 (CET) in Room Maillot. Prof. Escaned will also present the results from the DCR4Contrast trial and is available for questions during the EuroPCR 2023 Press Conference taking place on Tuesday 16 May from 08:05 – 09:15am CET in the Press Room on Level 3.

More information on these sessions and the full EuroPCR 2023 program can be found here.

In line with the company’s commitment to supporting its innovations with clinical evidence, Philips’ clinical partners will present new data during late-breaking sessions at EuroPCR that could help inform treatment for PCI patients.

Highlight innovations from Philips’ cardiology portfolio on display at EuroPCR include Philips Image Guided Therapy System – Azurion, Philips Interventional Applications Platform – IntraSight, next to visualization solutions such as Philips Precision Guidance System – SyncVision, Philips Dynamic Coronary Roadmap, live echo and live X-ray fusion tool – EchoNavigator, Pressure Guide Wire – OmniWire and its intravascular ultrasound (IVUS) catheters. Next to this, Philips will showcase atherectomy solutions, such as RX PTCA Scoring Balloon Catheter – AngioSculpt Evo, and its coronary laser atherectomy catheter – ELCA.

Live expert-led training sessions, symposiums and in-booth displays will give physicians and media insights into the latest developments in optimizing ULC-PCI procedures. Philips will also hold IVUS Simulation Sessions on recognizing different types of calcified plaque by intravascular ultrasound (IVUS) and optical coherence tomography. In the Philips Training Village visitors can learn more about how Philips solutions support interventionalists in minimizing the contrast load for the patient and physicians, and in performing interventional procedures with clarity and confidence using solutions such as IVUS, iFR, FFR and laser, improving cardiac care experiences for staff and patients.

For a full calendar of Philips events, session registration and to learn more about cardiology solutions being showcased in Philips Booth #F20 at EuroPCR 2023, please visit our website.

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 74,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 74,000 employees with sales and services in more than 100 countries. News about Philips can be found at